Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + cadonilimab + etoposide + carboplatin
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This drug combination consists of two bispecific antibodies, ivonescimab and cadonilimab, administered alongside etoposide and carboplatin (EC) chemotherapy. Ivonescimab (AK112) is a first-in-class bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Cadonilimab (AK104) is a bispecific antibody targeting PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This combination is being investigated in a Phase II clinical trial sponsored by Shanghai Pulmonary Hospital for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The regimen aims to leverage dual checkpoint inhibition and anti-angiogenesis to enhance anti-tumor activity, while the chemotherapy components (etoposide and carboplatin) provide cytotoxic effects through topoisomerase II inhibition and DNA alkylation.
- Other names
- Ivonescimab + Cadonilimab + ECAK112 + AK104 + etoposide + carboplatin
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAPDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on ivonescimab + cadonilimab + etoposide + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + cadonilimab + etoposide + carboplatin.